Hill-Rom completes $85M Volker buy; Neuros picks up RiverVest Venture Partners as investor;

@FierceMedDev: ZeroTo510 offers $50,000 grants for new Memphis, TN, biomedical startups. Report | Follow @FierceMedDev

> Hill-Rom Holdings ($HRC) has completed its $85 million purchase of Germany's Volker group. The buy is expected to strengthen Hill-Rom's channels and product offerings both in Europe and around the world. Hill-Rom release

> Neuros Medical, which is developing a device to block the chronic pain of amputees, has secured a new investor in RiverVest Venture Partners, which will participate in the startup's next funding round. Story

> U.K. diagnostics company Oxford Immunotec wants to put its first U.S. location outside of its Massachusetts headquarters in Memphis. Report

> ZONARE Medical Systems has promoted Timothy Marcotte, tapping him as its president and CEO. ZONARE release

> Organovo Holdings has completed a merger with Organovo, a company focused on the development of 3-D bioprinting technology for research and medical applications. In addition, Organovo has closed a private placement consisting of about 6.5 million units of its securities to qualified accredited investors for total gross proceeds of $6.5 million. Organovo release

> Every year in the U.S., roughly 785,000 people have a first heart attack, and 470,000 who have had one (or more) heart attacks go on to have another, according to the Centers for Disease Control and Prevention. However, BG Medicine's blood biomarker-based test CardioSCORE is designed to detect the people who are at a high risk of these cardiovascular events. News

And Finally... Scientists have used blood tests in diagnostic medicine since the late 19th century. However, blood derived from the human umbilical cord has yet to be fully mined for its vital health information. Rolf Halden, a researcher at Arizona State University's Biodesign Institute, is looking to change this situation. News

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.